(Q35755733)

10 August 2017

1 reference

title

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients (English)

1 reference

10 August 2017

0 references

1 reference

Judith E Raber-Durlacher

8

object named as

Judith Raber-Durlacher

1 reference

10 August 2017

Stephen T Sonis

1

1 reference

10 August 2017

Linda S Elting

2

1 reference

10 August 2017

Dorothy Keefe

3

1 reference

10 August 2017

Douglas E Peterson

4

1 reference

10 August 2017

Mark Schubert

5

1 reference

10 August 2017

Martin Hauer-Jensen

6

1 reference

10 August 2017

B Nebiyou Bekele

7

1 reference

10 August 2017

J Peter Donnelly

9

1 reference

10 August 2017

Edward B Rubenstein

10

1 reference

10 August 2017

Mucositis Study Section of the Multinational Association for Supportive Care in Cancer

11

1 reference

10 August 2017

International Society for Oral Oncology

12

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

100

1 reference

10 August 2017

1995-2025

1 reference

10 August 2017

9 Suppl

1 reference

The burdens of cancer therapy

10 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Irradiation induces increase of adhesion molecules and accumulation of beta2-integrin-expressing cells in humans.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Oxidative stress induced in pathologies: the role of antioxidants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Role of mast cells in early and delayed radiation injury in rat intestine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Radiation-induced oral mucositis in mice: strain differences

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Biology of oral mucosa and esophagus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Necrotizing colitis in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Recurrent typhlitis. A disease resulting from aggressive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Typhlitis associated with docetaxel treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Scoring irradiation mucositis in head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A scoring system for the quantitative evaluation of oral mucositis during bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Quantitative scale of oral mucositis associated with autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A new in vitro assay for quantitation of chemotherapy-induced mucositis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Effect of high-dose chemotherapy on intestinal permeability in humans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Combining studies using effect sizes and quality scores: application to bone loss in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Assessment of quality of life during intensive chemotherapy or bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Effect of oral glutamine supplementation during bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Influence of fractionated total body irradiation on mucosal toxicity in intensified conditioning regimens for autologous bone marrow transplantation in pediatric cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Soc

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Fractionated high-dose cyclophosphamide for advanced pediatric solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemothe

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Effective adjuvant chemotherapy for advanced nasopharyngeal carcinoma in children: a final update of a long-term prospective study in a single institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and Marrow Transplant Consortium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Accelerated hyperfractionation in patients with non-small cell bronchogenic cancers as a cost-effective and user- and patient-friendly schedule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Quantitative analysis of the oral complications of antileukemia chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase II study of UFT plus leucovorin in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Clinical characteristics and mechanisms involved in chemotherapy-induced oral ulceration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Patient self-reported and clinician-rated quality of life in head and neck cancer patients: a cross-sectional study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A prospective quality of life study of patients with oral or pharyngeal carcinoma treated with external beam irradiation with or without brachytherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Quality of life and oral function following radiotherapy for head and neck cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Oral health and quality of life among patients with head and neck cancer or haematological malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Intervent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Mature results from three large controlled studies with raltitrexed ('Tomudex').

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Chemotherapy-induced oral mucositis in adult leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, meth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A functional evaluation of patients treated for oral cancer. A prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Fluorouracil Combined With the Pure (6S)-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients With Advanced Colorectal Carcinoma: A Phase I-II Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

High dose methotrexate with and without BCG therapy in advanced head and neck malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Phase II trial of docetaxel for cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Management for patients with advanced T4 epidermoid carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

The effect of treatment duration in the local control of cervix cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Effect of pelvic irradiation on gastrointestinal function: a prospective longitudinal study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

A retrospective study of the effects of pelvic irradiation for gynecological cancer on anorectal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Severe late radiation enteropathy is characterized by impaired motility of proximal small intestine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Intestinal morphology and cytokinetics in pancreatic insufficiency. An experimental study in the rat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20162

7 January 2021

Identifiers

DOI

10.1002/CNCR.20162

1 reference

10 August 2017

1 reference